Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P07320
UPID:
CRGD_HUMAN
Alternative names:
Gamma-D-crystallin; Gamma-crystallin 4
Alternative UPACC:
P07320; Q17RF7; Q53R51; Q99681
Background:
Gamma-crystallin D, also known as Gamma-D-crystallin or Gamma-crystallin 4, plays a pivotal role in the vertebrate eye lens as one of the dominant structural components. These crystallins ensure the lens's transparency and refractive properties, crucial for normal vision.
Therapeutic significance:
Cataract 4, multiple types, including crystalline aculeiform, congenital cerulean, and non-nuclear polymorphic cataracts, are linked to variants affecting Gamma-crystallin D. Understanding the role of Gamma-crystallin D could open doors to potential therapeutic strategies for these visually impairing conditions.